May 25, 2016 8:04 AM ET

Biotechnology

Company Overview of Eagle Pharmaceuticals Inc.

Company Overview

Eagle Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers argatroban to treat heparin-induced thrombocytopenia; Ryanodex injectable suspension for the treatment of malignant hyperthermia; non-alcohol docetaxel injection, a chemotherapeutic agent for the treatment of breast, non-small cell lung, prostate, head, and neck cancers/gastric adenocarcinoma; and diclofenac-misoprostol. It develops EP-3101, a bendamustine ready to dilute (RTD) liquid; EP-3102, a bendamustine short infusion time RTD liquid for the treatment of chronic lymphocyt...

50 Tice Boulevard

Suite 315

Woodcliff Lake, NJ 07677

United States

Founded in 2007

62 Employees

Phone:

201-326-5300

Key Executives for Eagle Pharmaceuticals Inc.

Chief Executive Officer, President, Director and Member of Executive Committee
Age: 55
Total Annual Compensation: $874.2K
Chief Financial Officer
Age: 62
Total Annual Compensation: $449.8K
Chief Scientific Officer and Executive Vice President
Age: 56
Total Annual Compensation: $464.8K
Chief Medical Officer and Executive Vice President
Age: 54
Total Annual Compensation: $462.8K
Compensation as of Fiscal Year 2015.

Eagle Pharmaceuticals Inc. Key Developments

Eagle Pharmaceuticals Inc. Announces Unaudited Earnings Results for the First Quarter Ended March 31, 2016

Eagle Pharmaceuticals Inc. announced unaudited earnings results for the first quarter ended March 31, 2016. For the quarter, the company's total revenue was $29.6 million compared to $36.3 million for the three months ended March 31, 2015. Net loss was $0.9 million or $0.06 per basic and diluted share, compared to net income of $19.7 million or $1.38 per basic and $1.31 per diluted share for the three months ended March 31, 2015. Loss from operations was $0.9 million compared with income from operations of $20.1 million a year ago. Loss before income tax provision was $0.88 million compared with income of $20.1 million a year ago.

Eagle Pharmaceuticals Seeks Acquisitions

Eagle Pharmaceuticals Inc. (NasdaqGM:EGRX) is looking for acquisition opportunities. Tarriff , Scott L. Chief Executive Officer, President, Director and Member of Executive Committee of Eagle Pharmaceuticals says We will look at Eagle and see how well poised we are, again, with cash and a pipeline and no debt, and obviously the clean balance sheet. It gives us a lot of opportunity to acquire baskets of products or products.

Eagle Pharmaceuticals Seeks Acquisitions

Eagle Pharmaceuticals Inc. is seeking acquisitions. Scott Tariff, President and Chief Executive Officer of Eagle Pharmaceuticals said, we will look at Eagle Pharmaceuticals and see how well poised we are, again, with cash and a pipeline and no debt, and obviously the clean balance sheet. It gives us a lot of opportunity to acquire baskets of products or products.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3D Bio Holdings LLC United States
3D Biomatrix Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Bloomberg L.P. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Eagle Pharmaceuticals Inc., please visit www.eagleus.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.